Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper

• Published in: Supportive care in cancer Vol. 29; no. 2; pp. 1129 - 1138
• Main Authors: Cooksley, Tim, Font, Carme, Scotte, Florian, Escalante, Carmen, Johnson, Leslie, Anderson, Ronald, Rapoport, Bernardo
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2021; Springer; Springer Nature B.V
• Subjects: Ambulatory Care; Cancer; Cancer patients; Care and treatment; Clinics; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - diagnosis; Diagnosis; Epidemics; Febrile Neutropenia - diagnosis; Febrile Neutropenia - etiology; Febrile Neutropenia - therapy; Fever - etiology; Granulocyte Colony-Stimulating Factor - therapeutic use; Health aspects; Humans; Infection; Infections; Medicine; Medicine & Public Health; Neoplasms - complications; Neutropenia; Nursing; Nursing Research; Oncology; Pain Medicine; Pandemics; Prevention; Pulmonary embolism; Rehabilitation Medicine; Risk factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Special; Special Article; Telemedicine; COVID-19; Granulocyte colony-stimulating factor (G-CSF); Telemedicine; Cancer; Febrile neutropenia
• DOI: 10.1007/s00520-020-05906-y
• ISSN: 0941-4355

Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 pandemic. Dyspnea is a common emergency presentation in patients with cancer with a wide range of differential diagnoses, including pulmonary embolism, pleural disease, lymphangitis, and infection, of which SARS-CoV-2 is now a pathogen to be considered. Screening interviews to determine whether patients may be infected with COVID-19 are imperative to prevent the spread of infection, especially within healthcare facilities. Cancer patients testing positive with no or minimal symptoms may be monitored from home. Telemedicine is an option to aid in following patients without potential exposure. Management of complications of systemic anticancer treatment, such as febrile neutropenia (FN), is of particular importance during the COVID-19 pandemic where clinicians aim to minimize patients’ risk of infection and need for hospital visits. Outpatient management of patients with low-risk FN is a safe and effective strategy. Although the MASCC score has not been validated in patients with suspected or confirmed SARS-CoV-2, it has nevertheless performed well in patients with a range of infective illnesses and, accordingly, it is reasonable to expect efficacy in the clinical setting of COVID-19. Risk stratification of patients presenting with FN is a vital tenet of the evolving sepsis and pandemic strategy, necessitating access to locally formulated services based on MASCC and other national and international guidelines. Innovative oncology services will need to utilize telemedicine, hospital at home, and ambulatory care services approaches not only to limit the number of hospital visits but also to anticipate the complications of the anticancer treatments.